**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 43213

**Manuscript Type:** CASE REPORT

**Recurrent acute liver failure associated with novel *SCYL1* mutation: A case report**

Li JQ *et al*. *SCYL1* mutation and recurrent acute liver failure

Jia-Qi Li,Jing-Yu Gong, AS Knisely, Mei-Hong Zhang, Jian-She Wang

**Jia-Qi Li**, **Jing-Yu Gong, Mei-Hong Zhang,** Department of Pediatrics, Jinshan Hospital of Fudan University, Shanghai 201508, China

**Jian-She Wang,** The Center for Pediatric Liver Diseases, Children’s Hospital of Fudan University, Shanghai 201102, China

**AS Knisely**, Institut für Pathologie, Medizinische Universität Graz, Neue Stiftingtalstraße 6, Graz 8010, Austria

**ORCID number**: Jia-Qi Li (0000-0002-3150-3212); Jing-Yu Gong (0000-0002-1149-0979); AS Knisely (0000-0002-9173-539X); Mei-Hong Zhang (0000-0001-9656-7180); Jian-She Wang (0000-0003-0823-586X).

**Author contributions**:Wang JS designed the report and managed the patient; Li JQ was responsible for whole-exome sequencing data analysis and interpretation of sequence variants, validation by Sanger sequencing, and drafting the manuscript; Gong JY and Zhang MH were involved in the acquisition, analysis, and interpretation of clinical data; Knisely AS was responsible for the interpretation of histopathologic data and for manuscript editing; all authors have reviewed the manuscript and approved the final version to be submitted.

**Supported by** the National Natural Science Foundation of China, No. 81570468.

**Informed consent statement:** Informed consent was obtained from the parents of the patient.

**Conflict-of-interest statement**: The authors of this manuscript have no conflicts of interest to disclose.

**CARE Checklist (2016) statement**: The authors have read the CARE Checklist (2016), and the manuscript was prepared according to those guidelines.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source**: Unsolicited manuscript

**Corresponding author**: **Jian-She Wang, PhD, Professor**, The Center for Pediatric Liver Diseases, Children’s Hospital of Fudan University, 399 Wanyuan Road, Minhang District, Shanghai 201102, China. jshwang@shmu.edu.cn

**Telephone**: +86-21-64931171

**Fax**: +86-21-61143167

**Received:** November 20, 2018

**Peer-review started:** November 20, 2018

**First decision:** December 20, 2018

**Revised:** January 16, 2019

**Accepted:** January 29, 2019

**Article in press:** January 30, 2019

**Published online:** February 26, 2019

**Abstract**

***BACKGROUND***

Pediatric recurrent acute liver failure (RALF) with recovery between episodes is rare. Causes include autoimmune disease, which may flare and subside; intermittent exposure to toxins, as with ingestions; and metabolic disorders, among them the fever-associated crises ascribed to biallelic mutations in *SCYL1*, with RALF beginning in infancy. *SCYL1* disease manifest with RALF, as known to date, includes central and peripheral neurologic and muscular morbidity (hepatocerebellar neuropathy syndrome). Primary ventilatory and skeletal diseases also have been noted in some reports.

***CASE SUMMARY***

We describe a Han Chinese boy in whom fever-associated RALF began at age 14 mo. Bilateral femoral head abnormalities and mild impairment of neurologic function were first noted aged 8 years 6 mo. Liver biopsy after the third RALF episode (7 years) and during resolution of the fourth RALF episode (8 years 6 mo) found abnormal architecture and hepatic fibrosis, respectively. Whole-exome sequencing revealed homozygosity for the novel frameshift mutation c.92\_93insGGGCCCT, p.(H32Gfs\*20) in *SCYL1* (parental heterozygosity confirmed).

***CONCLUSION***

Our findings expand the mutational and clinical spectrum of *SCYL1* disease. In our patient a substantial neurologic component was lacking and skeletal disease was identified relatively late.

**Key words:** *SCYL1*; Recurrent acute liver failure; Whole-exome sequencing; Case report

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: An infant or child with recurrent acute liver failure may have biallelic mutation in *SCYL1*. A search for causes should include evaluation of this gene even if neurologic or skeletal disease is not appreciated.

Li JQ, Gong JY, Knisely AS, Zhang MH, Wang JS. Recurrent acute liver failure associated with novel *SCYL1* mutation: A case report. *World J Clin Cases* 2019; In press

**INTRODUCTION**

An unusual form of acute liver failure (ALF) occurs in children. Starting in infancy, episodes of hepatic insufficiency recur. These episodes may be preceded by fever (and thus be ascribed to antipyretics, in particular paracetamol)[1-3]*.* They may not be restricted to childhood[4,5] and may be fatal**[**6**]**.They are characterized by clinical-laboratory findings that include marked elevations in serum transaminase activity, severe coagulopathy, conjugated hyperbilirubinemia, and normal or only slightly elevated serum gamma-glutamyl transpeptidase activity[2,4].Hepatic crises, with less severe injury, also are seen[1-5]. The causes of recurrent ALF (RALF), as this disorder is termed, are incompletely understood, although instances have been ascribed to biallelic mutation in *SCYL1*(MIM: 607982)[7] or *NBAS* (MIM: 608025)[4]. *NBAS* disease is multisystem in some patients**[**3,6,8**]** and manifest only as RALF in others[2,4]. The few patients yet reported with*SCYL1* disease have exhibited isolated RALF in conjunction with a range of mild to more marked neurological phenotypes, including spinocerebellar ataxia and neurodegeneration[7,9-11]. In one, recurrent ventilatory failure was clinically prominent; RALF was not described[12].

We report a novel homozygous mutation in *SCYL1* in a Han Chinese boy who had RALF with onset in infancy and in whom, aged 8 years 6 mo, mild neurologic dysfunction and bilateral femoral head abnormalities were identified. Our observations expand the clinical and mutational spectrum of *SCYL1* disease.

**CASE PRESENTATION**

***Chief complaints***

A 7-year-old boy was admitted to our hospital due to recurrent episodes of ALF.

***History of present illness***

The patient was well till age 14 mo, when a fever was treated with the non-steroidal anti-inflammatory agent nimesulide. Jaundice developed, with elevated transaminase activity. Injury fell short of frank ALF, constituting instead a “liver crisis”. Two episodes of ALF followed at age of 3 years 6 mo and 6 years 3 mo, respectively (Table 1). Clinical, laboratory, and imaging-study findings between episodes were normal. At the age of 7 years, shortly after his third RALF episode, he was referred to our hospital for etiological diagnosis.

***History of past illness***

His parents and he denied any history of disease beyond those summarized above.

***Personal and family history***

He was born at term (weight 3 kg) by elective cesarean section after an uncomplicated pregnancy. He is the second child of a Han Chinese couple who deny consanguinity. His sibling, a brother, is well.

***Physical examination upon admission***

Physical examination on admission found no abnormalities.

***Laboratory examinations***

Blood, urine, and stool routine test results, viral serological markers (hepatotropic viruses, Epstein-Barr virus, cytomegalovirus, and human immunodeficiency virus 1), biomarkers of toxoplasma infection, of thyroid function, and of hepatobiliary injury, and values for cholesterol, triglycerides, creatine phosphokinase, glucose, ceruloplasmin, blood lactate, blood ammonia, carbonyldiamide, creatinine, uric acid, urine organic acids, alpha-fetoprotein, and immunoglobulin levels were unremarkable. The value of 25-(OH)D3 was 13.69 ng/mL (normal: 30-100 ng/mL).

***Imaging examinations***

Cranial magnetic resonance imaging showed a cyst (90 mm × 30 mm) in the cisterna magna and a relatively small cerebellum. The optic nerves were normal. Abdominal ultrasonography and echocardiography showed no significant abnormalities.

***Other examinations***

Findings on ophthalmologic evaluation were unremarkable. Liver biopsy found mildly abnormal architecture, without fibrosis, in a pattern suggesting disordered perfusion; no ultrastructural abnormalities were apparent. The Denver developmental screening test, which covers gross motor, language, fine motor-adaptive, and personal-social skills[13], found a low developmental quotient (< 47, normal > 70) and mental index (63, normal > 70).

***Whole-exome sequencing***

With the approval of the ethics committee of the Jinshan Hospital of Fudan University (Jinyi Lunli Keyan-2014-13-01) and after obtaining written informed consent from the parents of the patient, DNA was isolated from peripheral blood samples obtained from the proband, his brother, and his parents. Whole-exome sequencing was conducted as described[2] (Genesky Biotechnologies, Shanghai, China). Exomes were captured using a SureSelectXT Human All Exon V6 kit (Agilent Technologies, Foster, CA). Sequencing (250 bp paired-end reads) was performed using the Illumina hiseq2500 platform following the manufacturer’s instructions (Illumina, San Diego, CA). Burrows-Wheeler Aligner software (http://bio-bwa.sourceforge.net/) was used for read alignment (hg19; NCBI build 37; February, 2009). Variant calling was performed with Varscan (http://varscan.sourceforge.net/) and GATK HaplotypeCaller (https://software.broadinstitute.org/gatk/best-practices/). Mean coverage of the exome was 140× with 91% of the exome covered at least 10 times and 80% covered at greater than 20×. The proband’s variants were filtered for minor allele frequency < 1% against Thousand Genomes Project (http://www.1000genomes.org/home), NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/), Exome Aggregation Consortium Server (http://exac.broadinstitute.org/), and Genesky in-house databases. Variants in ALF-associated genes (Supplementary file 1) assessed by SIFT (http://sift.jcvi.org/), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), or MutationTaster[14] (http://www.mutationtaster.org/) as pathogenic and present in accord with inheritance modes were considered of interest. Sanger sequencing was used to confirm variants in the proband and to seek them in his parents and brother.

***Identification of a novel homozygous mutation in exon 1 in SCYL1***

The homozygous mutation c.92\_93insGGGCCCT, p.(H32Gfs\*20) in exon 1 in *SCYL1* (NM\_020680) was identified in the proband. His brother did not harbor this mutation. Each of their parents was heterozygous for the mutation, consistent with recessive inheritance. The mutation detected by exome sequencing was again identified on Sanger sequencing (Supplementary file 2). No other variant of interest was identified in any ALF-associated gene. The insertion of GGGCCCT between nucleotides 92 and 93 within exon 1 is predicted to result in the substitution of 19 abnormal amino acid residues (His32-Val50), followed by a stop codon at codon 51. MutationTaster predicts that this results in nonsense-mediated mRNA decay[14]. The variant is novel; it was not recorded in Exome Aggregation Consortium Server, NHLBI Exome Sequencing Project, Thousand Genomes Project, or Genesky in-house databases.

**FINAL DIAGNOSIS**

*SCYL1* disease.

**TREATMENT**

Supportive care during episodes of ALF or crises followed accepted guidelines and was not specific for any particular form of hepatic dysfunction. They included antibiotics to resist bacterial infection, ”liver protectant drugs” (D-glucurono-3,6-lactone, diammonium glycyrrhizinate, polyene phosphatidylcholine, *etc*.), cholagogues and choleretics (ursodeoxycholic acid, cholestyramine, *etc*.), prednisone, and supplementary fat-soluble vitamins A, D, E, and K.

**OUTCOME AND FOLLOW-UP**

The patient had his fourth episode of RALF at 8 years 5 mo (Table 1). During resolution of this episode, liver biopsy was conducted again. Alanine transaminase and aspartate aminotransferase values 2 d before liver biopsy were 91 IU/L (expected: 0-40 IU/L) and 476 IU/L (normal: 15-60 IU/L). Ballooning change of hepatocytes, some with cytoplasmic bile pigment, and hepatic fibrosis were observed. A comprehensive skeletal survey by radionuclide bone scan showed bilateral hip joint widening and bilateral femoral head flattening highly suggestive of bilateral femoral head necrosis. The patient failed finger-to-nose testing and Romberg testing, indicating cerebellar ataxia. However, muscle strength, muscular tension, stretch reflexes, deep sensory perception, and motor function were normal. At last evaluation, aged 8 years 7 mo, biomarker values in the proband were normal.

**DISCUSSION**

*SCYL1* encodes a kinase-like protein in the SCY1-like family[15,16]. SCYL1 may function as a scaffolding protein, involved in Golgi-to-endoplasmic reticulum retrograde transport and in Golgi integrity[17-19]. SCYL1 also acts in nucleocytoplasmic shuttling of tRNAs[20]. Biallelic mutations in *SCYL1* were first identified in 2015 as an important cause of a hepatocerebellar neuropathy syndrome (spinocerebellar ataxia, autosomal recessive 21; MIM:616719)[7].

To date, only 5 reports have described 14 patients harboring homozygous or compound heterozygous mutations in *SCYL1*[7**,**9-12**]**. Thirteen patients had similar hepatic features[7**,**9-11**]**; in the 14th, features of liver disease were present, but recurrent ventilatory failure dominated clinical illness[12]. Neurologic phenotypes varied, including peripheral neuropathy, ataxia, tremor, stuttering, speech-development delay, intellectual disability, microcephaly, and abnormal intracranial magnetic-resonance imaging findings. Six SCYL1-deficient patients had cerebellar atrophy and 2 siblings had optic nerve thinning[7,10,12].

Ourpatient had a classic hepatic phenotype, with one episode of liver crisis (aged 14 mo) and 3 episodes of acute liver failure (aged 3 years 6 mo, 6 years 3 mo, and 8 years 5 mo). Each episode was preceded by a febrile illness. Hepatobiliary-injury biomarker values recovered completely between episodes. Not all episodes of febrile illness led to hepatic crisis. Liver biopsy conducted after the third RALF episode (7 years) and during resolution of the fourth RALF episode (8 years 6 mo) revealed slightly abnormal architecture and hepatic fibrosis, respectively.

In our patient, relative cerebellar hypoplasia may be secondary to the cyst in the cisterna magna; vermis atrophy was not identified, and optic nerves were not thinned. Clinical neurologic features are at this writing minimal, with low developmental quotient and mental index, minor intracranial abnormalities, and abnormal coordination tests. These may worsen as the patient ages, or other abnormalities may yet declare themselves. Neurologic abnormalities usually are noted in *SCYL1* disease after liver disease has appeared (Supplementary file 3). To evaluate *SCLY1* in infants or children with RALF thus is indicated even if neurologic disease is inapparent. Long-term follow-up is necessary for best correlation between mutation and phenotypic consequences.

Worth noting is that skeletal abnormalities were observed in 8 of 14 *SCYL1*-deficiency patients. Skeletal phenotypes varied, including short stature, hip dysplasia, coronal clefting of ribs, scoliosis, lumbar lordosis, and thoracic vertebral abnormalities[9-11]. Ourpatient had bilateral femoral head disease, not reported before in association with *SCYL1* mutation. At least some of the skeletal abnormalities described appear primary rather than resulting from neuromuscular dysfunction, suggesting that such abnormalities may be an important clinical manifestation of *SCYL1* disease. Systemic skeletal examinations thus may be essential for children with *SCYL1* deficiency.

Early identification of the cause of ALF is fundamental for disease-specific management. In our patient, assignment of diagnosis to mutation in a specific gene shifted the context in which we viewed his findings on examination, changing our expectations for the course of what now can be considered as a multisystem disorder. For instance, during the fourth RALF episode, after genetic diagnosis, a comprehensive skeletal survey and more detailed neurologic examination were performed. Our care has become better focused and, with the progress of the disease, may perhaps permit orthopedic, physiatric, and neurologic intervention for directed support. In addition, genetic diagnosis can also help in prenatal screening.

Our patient is the first East Asian described with *SCYL1*-associated RALF. The *SCYL1* mutation c.92\_93insGGGCCCT, p.(H32Gfs\*20), which he harbors in homozygous state, is predicted to result in nonsense-mediated decay of a prematurely terminated RNA transcript. Although we lack direct evidence for lack of SCYL1 expression in our patient, we thus consider him the 15th identified patient with RALF due to *SCYL1* disease. We call attention to his clinical phenotype, with scant neurologic dysfunction identified thus far and relatively late-onset skeletal disease, although our findings are – without life-long follow-up – necessarily incomplete. We suggest that even if neurologic features of disease are few (“atypical” *SCYL1* disease), *SCYL1* defects should be considered as possibly underlying early-onset fever-related RALF. We also note as deserving further study the association between skeletal abnormalities and *SCYL1* disease.

**CONCLUSION**

Even if neurologic features of disease are few, SCYL1 defects should be considered as possibly underlying early-onset fever-related RALF. Systemic skeletal examinations are in order for children with *SCYL1* deficiency.

**ACKNOWLEDGEMENTS**

The authors are grateful for the support of the patient’s family and thank referring physicians, nurses, and technical staff.

**REFERENCES**

1 **Calvo PL**, Tandoi F, Haak TB, Brunati A, Pinon M, Olio DD, Romagnoli R, Spada M. NBAS mutations cause acute liver failure: when acetaminophen is not a culprit. *Ital J Pediatr* 2017; **43**: 88 [PMID: 28946922 DOI: 10.1186/s13052-017-0406-4]

2 **Li JQ**, Qiu YL, Gong JY, Dou LM, Lu Y, Knisely AS, Zhang MH, Luan WS, Wang JS. Novel NBAS mutations and fever-related recurrent acute liver failure in Chinese children: a retrospective study. *BMC Gastroenterol* 2017; **17**: 77 [PMID: 28629372 DOI: 10.1186/s12876-017-0636-3]

3 **Staufner C**, Haack TB, Köpke MG, Straub BK, Kölker S, Thiel C, Freisinger P, Baric I, McKiernan PJ, Dikow N, Harting I, Beisse F, Burgard P, Kotzaeridou U, Lenz D, Kühr J, Himbert U, Taylor RW, Distelmaier F, Vockley J, Ghaloul-Gonzalez L, Ozolek JA, Zschocke J, Kuster A, Dick A, Das AM, Wieland T, Terrile C, Strom TM, Meitinger T, Prokisch H, Hoffmann GF. Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. *J Inherit Metab Dis* 2016; **39**: 3-16 [PMID: 26541327 DOI: 10.1007/s10545-015-9896-7]

4 **Haack TB**, Staufner C, Köpke MG, Straub BK, Kölker S, Thiel C, Freisinger P, Baric I, McKiernan PJ, Dikow N, Harting I, Beisse F, Burgard P, Kotzaeridou U, Kühr J, Himbert U, Taylor RW, Distelmaier F, Vockley J, Ghaloul-Gonzalez L, Zschocke J, Kremer LS, Graf E, Schwarzmayr T, Bader DM, Gagneur J, Wieland T, Terrile C, Strom TM, Meitinger T, Hoffmann GF, Prokisch H. Biallelic Mutations in NBAS Cause Recurrent Acute Liver Failure with Onset in Infancy. *Am J Hum Genet* 2015; **97**: 163-169 [PMID: 26073778 DOI: 10.1016/j.ajhg.2015.05.009]

5 **Casey JP**, McGettigan P, Lynam-Lennon N, McDermott M, Regan R, Conroy J, Bourke B, O'Sullivan J, Crushell E, Lynch S, Ennis S. Identification of a mutation in LARS as a novel cause of infantile hepatopathy. *Mol Genet Metab* 2012; **106**: 351-358 [PMID: 22607940 DOI: 10.1016/j.ymgme.2012.04.017]

6 **Capo-Chichi JM**, Mehawej C, Delague V, Caillaud C, Khneisser I, Hamdan FF, Michaud JL, Kibar Z, Mégarbané A. Neuroblastoma Amplified Sequence (NBAS) mutation in recurrent acute liver failure: Confirmatory report in a sibship with very early onset, osteoporosis and developmental delay. *Eur J Med Genet* 2015; **58**: 637-641 [PMID: 26578240 DOI: 10.1016/j.ejmg.2015.11.005]

7 **Schmidt WM**, Rutledge SL, Schüle R, Mayerhofer B, Züchner S, Boltshauser E, Bittner RE. Disruptive SCYL1 Mutations Underlie a Syndrome Characterized by Recurrent Episodes of Liver Failure, Peripheral Neuropathy, Cerebellar Atrophy, and Ataxia. *Am J Hum Genet* 2015; **97**: 855-861 [PMID: 26581903 DOI: 10.1016/j.ajhg.2015.10.011]

8 **Kortüm F**, Marquardt I, Alawi M, Korenke GC, Spranger S, Meinecke P, Kutsche K. Acute Liver Failure Meets SOPH Syndrome: A Case Report on an Intermediate Phenotype. *Pediatrics* 2017; **139**: e20160550 [PMID: 28031453 DOI: 10.1542/peds.2016-0550]

9 **Smith ED**, Radtke K, Rossi M, Shinde DN, Darabi S, El-Khechen D, Powis Z, Helbig K, Waller K, Grange DK, Tang S, Farwell Hagman KD. Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. *Hum Mutat* 2017; **38**: 600-608 [PMID: 28106320 DOI: 10.1002/humu.23183]

10 **Lenz D**, McClean P, Kansu A, Bonnen PE, Ranucci G, Thiel C, Straub BK, Harting I, Alhaddad B, Dimitrov B, Kotzaeridou U, Wenning D, Iorio R, Himes RW, Kuloğlu Z, Blakely EL, Taylor RW, Meitinger T, Kölker S, Prokisch H, Hoffmann GF, Haack TB, Staufner C. SCYL1 variants cause a syndrome with low γ-glutamyl-transferase cholestasis, acute liver failure, and neurodegeneration (CALFAN). *Genet Med* 2018; **20**: 1255-1265 [PMID: 29419818 DOI: 10.1038/gim.2017.260]

11 **Shohet A**, Cohen L, Haguel D, Mozer Y, Shomron N, Tzur S, Bazak L, Basel Salmon L, Krause I. Variant in SCYL1 gene causes aberrant splicing in a family with cerebellar ataxia, recurrent episodes of liver failure, and growth retardation. *Eur J Hum Genet* 2019; **27**: 263-268 [PMID: 30258122 DOI: 10.1038/s41431-018-0268-2]

12 **Spagnoli C**, Frattini D, Salerno GG, Fusco C. On CALFAN syndrome: report of a patient with a novel variant in SCYL1 gene and recurrent respiratory failure. *Genet Med* 2018 [PMID: 30531813 DOI: 10.1038/s41436-018-0389-6]

13 **Frankenburg WK**. The Denver developmental screening test. *Dev Med Child Neurol* 1969; **11**: 260-262 [PMID: 5787726]

14 **Schwarz JM**, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 2014; **11**: 361-362 [PMID: 24681721 DOI: 10.1038/nmeth.2890]

15 **Kato M**, Yano K, Morotomi-Yano K, Saito H, Miki Y. Identification and characterization of the human protein kinase-like gene NTKL: mitosis-specific centrosomal localization of an alternatively spliced isoform. *Genomics* 2002; **79**: 760-767 [PMID: 12036289 DOI: 10.1006/geno.2002.6774]

16 **Liu SC**, Lane WS, Lienhard GE. Cloning and preliminary characterization of a 105 kDa protein with an N-terminal kinase-like domain. *Biochim Biophys Acta* 2000; **1517**: 148-152 [PMID: 11118629 DOI: 10.1016/S0167-4781(00)00234-7]

17 **Hamlin JN**, Schroeder LK, Fotouhi M, Dokainish H, Ioannou MS, Girard M, Summerfeldt N, Melançon P, McPherson PS. Scyl1 scaffolds class II Arfs to specific subcomplexes of coatomer through the γ-COP appendage domain. *J Cell Sci* 2014; **127**: 1454-1463 [PMID: 24481816 DOI: 10.1242/jcs.136481]

18 **Burman JL**, Hamlin JN, McPherson PS. Scyl1 regulates Golgi morphology. *PLoS One* 2010; **5**: e9537 [PMID: 20209057 DOI: 10.1371/journal.pone.0009537]

19 **Burman JL**, Bourbonniere L, Philie J, Stroh T, Dejgaard SY, Presley JF, McPherson PS. Scyl1, mutated in a recessive form of spinocerebellar neurodegeneration, regulates COPI-mediated retrograde traffic. *J Biol Chem* 2008; **283**: 22774-22786 [PMID: 18556652 DOI: 10.1074/jbc.M801869200]

20 **Chafe SC**, Mangroo D. Scyl1 facilitates nuclear tRNA export in mammalian cells by acting at the nuclear pore complex. *Mol Biol Cell* 2010; **21**: 2483-2499 [PMID: 20505071 DOI: 10.1091/mbc.E10-03-0176]

**P-Reviewer:** Chatzigeorgiou A, Nacif LS, Zheng YW

**S-Editor:** Wang JL **L-Editor:** Wang TQ **E-Editor:** Tan WW

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Clinical phenotype in three fever-associated acute liver failure episodes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Age 3y6mo** | **Age 6y3mo** | **Age 8y5mo** | **Range** |
| Febrile illness before ALF | Yes | Yes | Yes |  |
| Using antipyretics before ALF | Yes | No | Yes |  |
| Duration | >4 mo | >1 mo | >1 mo |  |
| Max TB (μmol/L) | 504.0 | 305.7 | 554.0 | 5.1-17.1 |
| Max DB (μmol/L) | 288.0 | 125.0 | 264.7 | 0-6.0 |
| Max ALT (IU/L) | 414 | 1865 | 881 | 0-40 |
| Max AST (IU/L) | 2050 | 4900 | 1648 | 15-60 |
| Max GGT (IU/L) | 117 | 39 | 70 | 7-50 |
| Max PT (s) | 24.9 | 29.5 | 26.7 | 11.0-14.5 |
| Hepatomegaly | Yes | Yes | Yes |  |
| Splenomegaly | No | No | Yes |  |
| Additional features | Antipyretic- induced hepatopathy diagnosed | Multi-organ involvement1 | Multi-organ involvement2 |  |

Multi-organ involvement1: Acute liver failure, severe acute pancreatitis, bilateral pneumonia, alimentary tract hemorrhage, and septic shock; Multi-organ involvement2: Acute liver failure, bronchopneumonia, moderate anemia, ventricular premature beats, hypokalemia, hyponatremia, and bilateral femoral abnormalities. ALF: Acute liver failure; TB: Total bilirubin; DB: Direct bilirubin; ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: gamma-glutamyl transpeptidase; PT: Prothrombin time; Max: Maximum.